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We previously reported that vascular endothelial growth factor (VEGF)-dependent activation of phospho-
lipase C1 (PLC) regulated tube stability by competing with phosphoinositide 3-kinase (PI3K) for their
common substrate. Here we describe an additional mechanism by which PLC promoted regression of tubes
and blood vessels. Namely, it increased the level of autotaxin (ATX), which is a secreted form of lysophos-
pholipase D that produces lysophosphatidic acid (LPA). LPA promoted motility of endothelial cells, leading to
disorganization/regression of tubes in vitro. Furthermore, mice that under- or overexpressed members of this
intrinsic destabilization pathway showed either delayed or accelerated, respectively, regression of blood vessels.
We conclude that endothelial cells can be instructed to engage a PLC-dependent intrinsic destabilization
pathway that results in the production of soluble regression factors such as ATX and LPA. These findings are
likely to potentiate ongoing efforts to prevent, manage, and eradicate numerous angiogenesis-based diseases
such as proliferative diabetic retinopathy and solid tumors.
The formation of new blood vessels from the existing vas-
culature (angiogenesis) is an elegant process that is the subject
of intense scientific inquiry. Some of the agents that induce
angiogenesis have been identified, and this information has led
to development of novel therapies for endemic human diseases.
For instance, vascular endothelial growth factor A (VEGF-A)
promotes angiogenesis, and approaches to block VEGF-A ac-
tion are the preferred treatment option for patients with the
wet form of macular degeneration (2, 9, 11).
Angiogenesis is a program of deliberately orchestrated cel-
lular events (5). The first step is destabilization of a quiescent
vessel that is associated with loss of pericytes. Endothelial cells
within the vessel relax their intercellular interactions and mi-
grate out into areas where the surrounding extracellular matrix
has been degraded by proteases. Proliferation of endothelial
cells and recruitment of circulating endothelial precursors gen-
erate the new vessel. In the final step, the new vessel undergoes
stabilization and thereby concludes the program.
In contrast to the wealth of information on how angiogenesis
is initiated, relatively little is known regarding the regression of
vessels. There are several well-known mechanisms for blood
vessel regression. The first to be discovered was regression
resulting from a decline in the level of proangiogenic factors
(1, 3, 20). Vessels can also regress without an obvious shortage
of proangiogenic factors (14, 15, 33, 38), and this phenomenon
heralds the existence of additional mechanisms. For instance,
macrophages and pericytes direct regression of hyaloid vessels
by secreting Wnts and angiopoietin 2, respectively (21, 22, 25,
35). Elucidating how vessel stability/regression is governed is
likely to guide the development of therapies to induce regres-
sion of existing pathological vessels that are an Achilles’ heel of
human diseases (solid tumors and various eye diseases) that
afflict a large number of people worldwide.
One of the intracellular signaling cascades that VEGF trig-
gers is initiated by phospholipase C (PLC) (27). Blocking
VEGF-dependent activation of PLC suppresses many of the
cellular events intrinsic to angiogenesis (40), and mice express-
ing a VEGF receptor unable to activate PLC fail to properly
organize blood vessels and die in utero (37). In an in vitro
vasculogenesis model in which endothelial cells are the only
cell type, VEGF-dependent activation of PLC resulted in
regression of tubes (14). Together these studies demonstrate
that PLC is a key effector for VEGF-dependent responses. In
addition, they suggest that PLC-dependent events govern ves-
sel stability/regression.
Autotaxin (ATX) was originally identified as a tumor cell
motility factor and has more recently been implicated in an-
giogenesis. For instance, ATX-transfected Ras-transformed
NIH 3T3 cells or purified ATX increased angiogenesis in an in
vivo Matrigel plug assay (30). Furthermore, VEGF increases
expression of ATX (18, 34); ATX was identified as one of the
genes that control the angiogenic response to basic fibroblast
growth factor (bFGF) (36). Finally, ATX-deficient mice die
during embryogenesis and display a vascular defect (41, 48).
ATX, or nucleotide pyrophosphatase/phosphodiesterase 2
(NPP2), is a plasma lysophospholipase D (lysoPLD), which
generates lysophosphatidic acid (LPA) from lysophosphatidyl
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choline (LPC) (43, 44). LPA signals through G protein-cou-
pled receptors and is degraded through dephosphorylation by
lipid phosphate phosphatases (LPPs) (39, 47). While ATX is
implicated in angiogenesis, the ATX-regulated steps of the
angiogenic program have not been elucidated.
In this report we describe our serendipitous discovery that
the stability/regression of tubes and blood vessels is regulated
by an intrinsic destabilization/regression pathway that involves
PLC, ATX, and LPA.
MATERIALS AND METHODS
Antibodies and reagents. Anti-mouse and anti-rabbit antibodies conjugated to
horseradish peroxidase were obtained from Amersham Biosciences (Piscataway,
NJ). Rabbit polyclonal anti-Erk antibody was obtained from Cell Signaling
Technology (Beverly, MA). Anti-Flag antibody was purchase from Sigma.
The RasGAP antibody was crude polyclonal rabbit antiserum that was pre-
viously described (45). The anti-ATX antibody (84b) was affinity purified and
raised against a peptide in the C terminus of ATX. Cyclosporine (CS) and
INCA-6 were purchased from Calbiochem (San Diego, CA). FK-506 was pur-
chased from A.G. Scientific (San Diego, CA). The LPP1 cDNA was a gift from
Susan Pyne (Strathcylde Institute of Pharmacy and Biomedical Science, Glas-
gow, United Kingdom). Recombinant VEGF-A was purchased from Upstate
Biotechnology Inc. All other chemicals and reagents were obtained from Sigma
(St. Louis, MO) unless otherwise indicated.
Cell culture. Retinal endothelial cells (BRECs) were isolated from bovine eyes
as described previously (10, 16). BRECs were maintained in EBM (Lonza,
Walkersville, MD) supplemented with 10% horse serum (Clonetics), 80 U/ml
penicillin-streptomycin C (Irvine Scientific, Santa Ana, CA), and 12 g/ml bo-
vine brain extract (Clonetics). The cells were plated on plastic coated with 50
g/ml bovine fibronectin and incubated at 37°C in 5% CO2. For all experiments,
cells were used between passages 7 and 10. Human intestinal microvascular
endothelial cells (HIMECs) were isolated as previously described (4). Briefly,
HIMECs were obtained from normal areas of the intestines of patients admitted
for bowel resection. HIMECs were isolated by enzymatic digestion and subse-
quently cultured in MCDB131 medium (Sigma) supplemented with 20% fetal
bovine serum (BioWhittaker, Walkersville, MD), antibiotics (BioWhittaker),
heparin (Sigma), and endothelial cell growth factor (Roche Applied System,
Indianapolis, IN). Cultures of HIMECs were maintained at 37°C in 5% CO2.
HIMECs were used between passages 7 and 12. Human umbilical vein endothe-
lial cells (HUVECs) were purchased from Clonetics and maintained in EGM-2
(Clonetics) with low-serum growth factor supplement (Clonetics). For all exper-
iments, HUVECs were used between passages 5 and 7.
bFGF pellet preparation and corneal micropocket assay. bFGF pellets (80
ng/pellet; R&D Systems, Minneapolis, MN) were made of the slow-release
polymer Hydron (polyhydroxyethylmethacrylate), which contained a mixture of
45 ng/pellet of sucralfate (Sigma) as previously described by Kenyon et al. (20).
Briefly, a suspension of bFGF and sucralfate was made and dried for 8 min. To
this suspension, 10 l of 12% Hydron in ethanol was added. The suspension was
then deposited onto a sterilized nylon mesh (LAB Pak; Sefar America, Depew,
NY) and embedded between the fibers. The resulting grid of 10- by 10-mm
squares was allowed to dry, and 30 to 40 uniformly sized pellets of 0.4 by 0.4 by
0.2 mm were selected for the assay. Corneal micropockets were created with a
modified von Graefe knife. Hydron pellets containing 80 ng of human bFGF
were implanted into the corneal pockets. Corneal neovascularization was exam-
ined daily and photographed with a slit lamp biomicroscope (Nikon FS-2; Nikon,
Tokyo, Japan) on days 0, 7, 14, and 21 after pellet implantation. The blood
vessels were quantitated using the NIH Image program (NIH, Bethesda, MD).
Statistical analysis was performed with the Student t test.
Measurement of hyaloid vessel regression. At postnatal day 1 (P1), P5, P10,
P15, and P20, both PLC/ and PLC/ mice were euthanized, and the eyes
were removed, fixed in 4% formaldehyde, and embedded in methyl methacrylate.
For ATXTg/ and ATX/ mice, the eyes at postnatal days 1, 3, 7,10, and 22
were used. Serial sections (3 to 10 m) of whole eyes were cut sagitally, through
the cornea and parallel to the optic nerve. Sections were stained with hematox-
ylin and eosin. The total number of hyaloid vessels in 10 slides from each eye was
counted by a masked observer. The Student t test was used for the statistical
analysis.
Migration assay using Boyden chambers. Cell migration was evaluated using
a quantitative cell migration assay kit (Millipore, Billerica, MA) following the
manufacturer’s instructions. Briefly, the Boyden chamber assay kit consists of a
hollow plastic chamber sealed at one end with a porous membrane. BRECs were
seeded in this hollow chamber in the presence of serum-free medium. The
hollow chamber resided in another chamber filled with either vehicle, 10% horse
serum, 1 M LPA, or 25 ng/ml VEGF-A. Cells were allowed to migrate over-
night through the pores to the other side of the membrane. The inner tube was
then removed and carefully washed, and any nonmigratory cells inside the mem-
brane were carefully scraped away. Cells that had migrated to the opposite side
of the membrane were stained, extracted and quantified with a spectrophotom-
eter (Spectra Max M5; Molecular Devices, Sunnyvale, CA).
Time-lapse images. HIMECs were subjected to a tube formation assay. After
6 h, the cells were supplemented with medium containing 10 M LPA. The
culture plate was placed in an incubator that was assembled with an Axio
Observer D1 inverted microscope (Carl Zeiss). The temperature inside the
incubator was maintained at 37°C with 5% CO2. Images were captured with an
AxioCam digital camera (Carl Zeiss) and processed with Adobe Photoshop.
Tube formation assay. The tube formation assay was performed as previously
described (14, 16). The average tube length was routinely 15 to 30 mm in either
BRECs or HUVECs exposed to VEGF-A or in platelet-derived growth factor
receptor (PDGFR)-expressing BRECs responding to endogenous PDGF.
Transfection of siRNA-ATX oligonucleotides. Small interfering RNA (siRNA)
oligonucleotides that target ATX and a nontargeting siRNA pool were pur-
chased from Dharmacon (Lafayette, CO) and resuspended according to the
manufacturer’s instructions. For transfection, 7  104 HUVECs were plated
onto solidified collagen gel and incubated for 16 to 18 h in culture medium.
siRNA-ATX and siRNA control oligonucleotides at 100 nM were mixed with
TransPass R2 transfection reagent (New England BioLabs, Beverly, MA) 20 min
before transfection. Cells were washed once with Dulbecco modified Eagle
medium (DMEM) (GIBCO BRL, Gaithersburg, MD), and then the transfection
reagent mixture was added. After 4 h of incubation, the top collagen gel was
added. After 1 h, 2 ml of culture medium was added and the cultures were
incubated overnight. Cells were then incubated for an additional 24 h in freshly
added culture medium.
Stable expression of PDGFR mutants. The Y40/51 and Y40/51/21 constructs
were previously constructed and characterized (46). The PDGFR cDNAs were
subcloned into the retroviral vector pLXSN. The pLXSN empty vector and
PDGFR mutants/pLXSN constructs were transfected into 293GPG cells. The
virus-containing supernatant was collected for 5 days, concentrated (25,000  g,
90 min, 4°C), and used as described previously (31). Cells were infected and
selected on the basis of proliferation in the presence of G418 (1 mg/ml).
Western blot analysis and immunoprecipitation. For Western blot analysis of
anti-Flag-LPP1, 2 106 BRECs were plated into a 10-cm tissue culture plate and
incubated for at least 18 h in culture medium. Total cell lysates were prepared
and Western blot analysis was performed as described previously (16).
To reprobe a blot, the blot was first stripped by incubating for 30 min at 60°C
in a buffer containing 6.25 mM Tris-HCl, pH 6.8, 2% SDS, and 100 mM -mer-
captoethanol and then reprobed with the desired primary antibody.
Western blot analysis of cells that had organized into tubes was performed as
follows. Cells were recovered following a collagenase treatment (collagenase
type I-S from Sigma; 281 units per well for 20 min at 37°C), which dissolved the
collagen gel. The cells were rinsed three times with ice-cold phosphate-buffered
saline (PBS), and total cell lysates were made and subjected to Western blot
analysis as described above.
Mice. PLC/ mice were a gift from Demin Wang (Blood Center of Wis-
consin, Milwaukee, WI) (23). PLC/ mice and their wild-type (WT) litter-
mates were derived from breeding heterozygotes. ATXTg/ and ATX/ mice
were generated as previously described (32). All animal studies were approved by
the Institutional Animal Care and Use Committee of the Schepens Eye Research
Institute (Harvard Medical School) and the University of Kentucky.
RESULTS
Developmental and pathological vessel regression is delayed
in PLC/ mice. We previously established and described an
in vitro model of vasculogenesis in which primary endothelial
cells organized into tubes in a VEGF-dependent manner (16).
After a period of apparent stability, the tubes regressed despite
the continued presence of serum and VEGF. Consistent with
the idea that regression was not the inevitable consequence of
starvation-induced apoptosis, the tubes regressed prior to apop-
tosis (14). Importantly, regression appeared to be a deliberate
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response, since it required VEGF-dependent activation of
PLC (14). To assess whether these in vitro principles extended
to the in vivo setting, we tested whether blood vessel regression
was delayed in PLC heterozygous mice.
We first compared regression of hyaloid vessels, which is a
developmentally driven phenomenon in newborn mice. These
vessels are found in the vitreous along the inner limiting mem-
brane of the retina (vasa hyaloidea propria) and around the
developing lens capsule (tunica vasculosa lentis) (17). Hyaloid
vessels naturally regress after birth, and regression is complete
by postnatal day 30 (P30) (17). WT and PLC/ mice were
sacrificed at P1, P5, P10, P15, and P20; the eyes were enucle-
ated; and the hyaloid vessels in approximately 10 serial sections
were counted. It was not possible to perform these experiments
on mice lacking both alleles of PLC because this genotype
results in embryonic lethality (23). Despite only a 50% reduc-
tion of PLC, we observed a significant delay in the regression
of the hyaloid vessels at days 1, 5 and 10 in the PLC/ mice
(Fig. 1A and B). While macrophages are essential for promot-
ing regression of these vessels (21, 22), this did not seem to be
the explanation for the delay in regression because at the P6
time point there were more macrophages associated with ves-
sels in the PLC/ mice than in controls (data not shown).
Thus, developmentally programmed regression of the hyaloid
vasculature was dependent on PLC.
To determine whether PLC contributed to regression of
pathological vessels, we induced corneal neovascularization
and focused on the regression of these neovessels. In wild-type
mice, the bFGF-impregnated pellet (80 ng/pellet) induced
peak neovascularization at day 7, and these vessels subse-
quently regressed within a 2-week time frame (Fig. 1C and D).
The neovascular response was comparable in the PLC/
mice, whereas regression was significantly delayed at both the
14- and 21-day time points (Fig. 1C and D). These results
demonstrate that reducing the level of PLC expression in
mice slowed developmental and pathological regression in at
least certain vascular beds. We conclude that there was a good
concordance between the in vitro model and two in vivo set-
tings with respect to a role for PLC in regulating regression.
The mechanism by which PLC promotes regression in-
volves more than just competing with PI3K for substrate. In
our standard in vitro assay, endothelial cells organize into tubes
(five to seven cells surrounding a lumen) (16), and this re-
sponse is dependent on VEGF-A, which activates both phos-
phoinositide 3-kinase (PI3K) and PLC (14). While PI3K pro-
moted formation of tubes, PLC destabilized tubes by
FIG. 1. Regression of hyaloid and corneal vessels is delayed in PLC/ mice. (A) At postnatal days 1, 5, 10, 15, and 20, PLC/ and PLC/
mice were euthanized, and the eyes were removed, fixed, and sectioned. Sections were stained with hematoxylin and eosin; representative sections
at postnatal day 5 are shown in the upper panels. High-magnification photos are shown in the lower panels. This section was through the optic nerve
and therefore included the major retinal artery. Arrows indicate the hyaloid vessels. The bar is 50 m. (B) The nuclei of hyaloid vessels in the
indicated number of mice were counted; the horizontal bar denotes the average. There were statistically significant differences between the two
groups at the first three time points. (C) A bFGF pellet was introduced into the corneas of PLC/ and PLC/ mice, and the neovascular
response was photographed at the indicated times. Representative eyes at day 14 are shown. The pellet is to the right of the asterisk. (D) The total
vessel length was measured and quantified; each data point represents an individual mouse. Regression was slower in the PLC/ mice, and this
difference was statistically significant on days 14 and 21.
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competing with PI3K for their common substrate, phosphoti-
dylinositide-4,5-bisphosphate (PtdIns-4,5-P2) (14). Since PLC
is also capable of initiating numerous signaling pathways, we
considered whether these downstream events contributed to
regression. While two general protein kinase C inhibitors (cal-
phostin C and bisindolylmaleimide 1) had no effect on tube
regression (data not shown), pharmacologically suppressing
the activity of calcineurin (a calcium-regulated phosphatase
downstream of PLC [12]) after tubes had formed greatly
attenuated tube regression (Fig. 2A to D). In contrast to their
effect on tube regression, the calcineurin inhibitors did not
influence tube formation (Fig. 2A to D). These studies indicate
that competition with PI3K was only a partial answer for how
PLC facilitated tube regression and suggest that downstream
signaling events were making an essential contribution.
If VEGF activates PLC, which promotes regression of
FIG. 2. Activation of the PLC/calcineurin pathway increases production of a secreted regression factor. BRECs were subjected to the standard
VEGF-A-driven tube assay, and once tubes had formed, cyclosporine (CS) (1 M) (A and B), FK-506 (1 M) (C), INCA-6 (10 M) (D), or buffer was
added. After 24 h, three randomly selected fields were photographed (representative photos are shown in panel A) and tube lengths were measured (B
to D). The bar graphs show the means  standard deviations for three wells/treatment. (E to G) Conditioned medium experiments. To generate
conditioned medium (CM), parental BRECs (E) or BRECs stably expressing either the Y40/51/21 PDGFR mutant (F) or the Y40/51 PDGFR mutant
(G) were plated in a collagen sandwich gel, and then medium containing 2.5 ng/ml VEGF-A (only for parental BRECs) or buffer was added. Like most
endothelial cells, BRECs express PDGF, and therefore introducing the PDGFR established an autocrine loop that drove spontaneous tube formation
(14). After 48 h, CM was collected and added to 18- to 24-h-old cultures of tubes that had been independently generated using the Y40/51 cells.
 indicates supplementation with mock conditioned medium that was generated in collagen sandwich gels that did not have cells. After 24 h, three
randomly selected fields were photographed and tube lengths were measured. The bar graphs show the means  standard deviations for three
wells/treatment. (Bottom right) Diagram of the signaling proteins that bind to the PDGFR mutants used in this set of experiments (14); the Tyr
phosphorylation sites that are required for binding are indicated. The filled squares symbolize tyrosine-to-phenylalanine mutations, whereas intact
phosphorylation sites are represented by “P.” The WT PDGFR associates with Src, Grb2, GAP, SHP-2, PI3K, and PLC. The Y40/51 mutant associates
with Src, Grb2, and PI3K but not with GAP, SHP-2, or PLC. The Y40/51/21 mutant associates with Src, Grb2, PI3K, and PLC but not with GAP or
SHP-2. The key difference between this pair of receptor mutants is that Y40/51/21 engages PLC, whereas Y40/51 does not.
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tubes, then why does VEGF also promote the formation of
tubes (16)? One possibility was that PLC is not activated
while tubes are forming; however, this appeared not to be the
case (14). A second possibility is that PLC promotes the
gradual production of a secreted regression factor; tubes could
form while the level of the regression factor was low, but as the
level increased, tubes regressed. We performed the following
series of experiments to test whether the conditioned medium
contained factors capable of inducing regression. We used not
only the parental BRECs, in which tube formation was driven
by endogenous VEGFRs that were activated by exogenously
added VEGF-A, but also BRECs stably expressing the plate-
let-derived growth factor receptor (PDGFR) signaling mutants
shown in Fig. 2 (bottom right). Like most endothelial cells,
BRECs express PDGF, and introduction of PDGFR estab-
lishes an autocrine loop that promotes tube formation (VEGF
is not required) (16). The reason to use this experimental
system was that it enabled generation of stable tubes. Expres-
sion of a PDGFR mutant (Y40/51) that activated PI3K but not
PLC resulted in stable tubes (14), which were used to test
conditioned medium for regression activity. Medium from pa-
rental BRECs that had been cultured in the VEGF-A-driven
tube assay for 48 h was collected and placed on stable tubes. As
shown in Fig. 2E, this conditioned medium promoted regres-
sion of tubes, whereas conditioned medium collected from
Y40/51 tubes did not (Fig. 2G). To test whether the presence
of the regression activity in the conditioned medium was de-
pendent on receptor-mediated activation of PLC, we com-
pared conditioned medium from BRECs expressing PDGFRs
that activate PI3K (Y40/51) with that from BRECs expressing
PDGFRs that activate both PI3K and PLC (Y40/51/21). As
shown in Fig. 2F and G, only the conditioned medium from the
Y40/51/21 tubes induced regression. Taken together, these
findings demonstrate that there was a regression factor in the
conditioned medium and that its presence/activity was depen-
dent on receptor-triggered activation of PLC.
Autotaxin induces regression of tubes. To identify the regres-
sion factor, we considered the events downstream of calcineurin.
One of the calcineurin substrates is the transcription factor
NFAT, which gains access to the nucleus following dephosphor-
ylation by calcineurin (12). In the presence of INCA-6, which
prevents calcineurin from interacting with NFAT, tubes failed to
regress (Fig. 2D). These data suggested that the regression
factor was an NFAT-regulated gene product. While there are
many such genes, we considered autotaxin (ATX) for the fol-
lowing reasons. First, ATX is an NFAT-regulated gene (6).
Second, ATX is essential for formation/remodeling of blood
vessels during embryogenesis (41, 48). Similarly, purified ATX
increases the vessel density of subcutaneously implanted
Matrigel plugs (30). ATX’s proangiogenic action could result
from permitting vessels to form, enhancing their formation,
preventing their regression, or a combination of these possi-
bilities. Third, ATX is a motility factor for many cell types;
inducing migration of cells within a tube would likely lead to its
disorganization, which may be interpreted as regression in our
tube assay.
We performed a series of experiments to test the idea that
ATX was the regression factor, and the results strongly sup-
ported this concept. First, ATX gradually increased over the
time course of the VEGF-A-driven tube assay (Fig. 3A); the
same trend was observed for ATX mRNA (data not shown).
Second, accumulation of ATX was dependent on activation of
PLC; ATX accumulated in tubes that were organized from
cells that could activate PLC but remained undetectable
when the receptor could not activate PLC (Fig. 3A). Third,
accumulation of ATX was inhibited when activation of cal-
cineurin was blocked (Fig. 3A). Fourth, addition of an ATX
inhibitor (L-histidine [10 mM]) (8) prevented regression of
tubes, whereas control tubes (treated with L-glycine [10 mM])
regressed (Fig. 3B). Since highly specific ATX inhibitors are
currently unavailable, we chose an siRNA-based approach to
complement the inhibitor studies. When ATX expression was
partially suppressed in HUVECs using siRNA, regression was
attenuated (Fig. 3C). Fifth, recombinant, purified ATX (wild
type [0.3 g/ml]) induced regression of stable tubes (assembled
from BRECs expressing the Y40/51 PDGFR), whereas the
same dose of catalytically inactive ATX (T210A) induced re-
gression poorly (Fig. 3D). Furthermore, HUVEC and BREC
tubes organized in the presence of VEGF-A (which regress
spontaneously) regressed faster in the presence of exogenously
added catalytically active ATX than with the T210A mutant
(data not shown). Taken together, the results of these experi-
ments indicate that ATX was critically involved with regression
of tubes.
Lysophosphatidic acid mediates tube regression. ATX is an
enzyme that converts lysophosphatidylcholine (LPC) into ly-
sophosphatidic acid (LPA); it can also hydrolyze sphingo-
sylphosphorylcholine (SPC) to produce sphingosine-1-phos-
phate (S1P) (7). To test whether either of these ATX products
were responsible for tube regression, we added each of them to
the tube assay mixture after tubes had formed. LPA promoted
regression of stable tubes (BRECs expressing Y40/51 PDGFR)
in a concentration-dependent manner (Fig. 4A and data not
shown). Furthermore, LPA accelerated spontaneous regres-
sion of tubes organized from parental BRECs and induced
regression in CS-stabilized tubes (Fig. 4B and C). Time-lapse
images show that LPA induced collapse of the tubes (Fig. 4D).
In contrast, tube regression was insensitive to exogenously
added S1P (Fig. 4E and F). These data indicate that LPA
instead of S1P was the relevant ATX effector, and such a
conclusion is consistent with the following four observations:
(i) ATX hydrolyzes LPC more efficiently than SPC (7); (ii) the
plasma level of LPC (the substrate for generating LPA) is
1,000 times higher than that of SPC (the substrate for gen-
erating S1P) (24); (iii) S1P is undetectable in embryos of mice
missing both of the sphingosine kinase genes (29), which sug-
gests that ATX does not contribute to S1P production in vivo;
and (iv) the plasma concentration of S1P is unchanged in
ATX/ mice compared to ATX/ mice, whereas that of
LPA is reduced 50% (41, 48).
To pursue the idea that LPA was the critical ATX product,
we overexpressed LPP1, a member of a family of lipid phos-
phate phosphatases (LPPs) that dephosphorylates LPA and
thereby neutralizes it (26). BRECs that overexpressed LPP1
formed tubes normally in response to VEGF-A; however, they
failed to regress (Fig. 4G). Moreover, purified ATX was un-
able to promote regression unless in the presence of purified
LPC or serum (which is a source of LPC) (Fig. 4H and I and
3D). Finally, exogenously added LPA promoted migration of
BRECs (Fig. 4J) and HUVECs (data not shown). Taken to-
VOL. 30, 2010 AUTOTAXIN INDUCES VESSEL REGRESSION 2405
gether, these data indicate that LPA was the critical ATX
product.
Regression is accelerated in ATX transgenic mice. Since
ATX regulated tube regression in our in vitro model system, we
considered whether ATX contributed to regression of blood
vessels in vivo. To this end, we compared hyaloid vessel regres-
sion in wild-type and ATX transgenic mice. The transgene is
driven by the 	1-antitrypsin promoter, and the plasma level of
ATX was elevated (1.3- to 3.6-fold). Similarly, the transgenic
mice had increased amounts of ATX activity and LPA in their
plasma (32). These mice are fertile and have no overt pheno-
type with the exceptions of bleeding diathesis and attenuation
of thrombosis. The overall development of the eye was com-
parable in the wild-type and transgenic mice (Fig. 5A). In
contrast, regression of hyaloid vessels was accelerated in trans-
genic mice at days 1 and 3 (Fig. 5B). These observations indi-
cate that an increase in the circulating level of ATX/LPA
promoted regression of blood vessels in vivo.
DISCUSSION
We previously observed that PLC was required for regres-
sion of tubes in an in vitro assay (14). In this study we extended
this observation to the in vivo setting: regression of develop-
mental and pathological blood vessels was delayed in mice
heterozygous for PLC. In the in vitro setting, ATX/LPA ap-
peared to be the effectors of PLC-directed regression, and in
the in vivo setting, increasing the circulating level of ATX/LPA
promoted regression of hyaloid vessels.
The fact that there are two sources of ATX/LPA, intrinsic
and extrinsic, leads to the question of which of them is respon-
sible for driving regression. Our data in the in vitro setting
suggest that both are important. Knocking down the cell’s
ability to make ATX blunted regression (Fig. 3C), even though
this manipulation presumably did not alter that amount of
ATX present in the serum-containing medium. Thus, cell-
produced ATX was contributing. On the other hand, tubes
regressed in response to exogenously added LPA. Further-
more, in the absence of serum-containing medium, tubes did
not regress, even though they made ATX, and adding LPC (so
that they could generate LPA) did not promote regression
(unpublished observation). This combination may have re-
sulted in insufficient LPA production, since increasing the
amount of ATX (by adding purified ATX) induced regression.
We concluded that both extrinsic and intrinsic sources of ATX/
LPA were contributing to regression of tubes, and the com-
bined input may be necessary to bring the level of LPA above
the threshold required to drive regression.
In the in vivo setting, we observed that increasing the circu-
lating level of ATX was sufficient to accelerate regression of
hyaloid vessels (Fig. 5). However, this appears not to be the
only way to regulate regression of this vascular bed. There was
no difference in the plasma level of ATX in PLC/ and
PLC/ pups at the P6 time point (unpublished observations)
FIG. 3. ATX is necessary and sufficient for regression of tubes. (A) Parental BRECs or BRECs stably expressing the Y40/51/21 or Y40/51
PDGFR mutant were subjected to a tube assay with or without CS (1 M). At the indicated times, total cell lysates were made and subjected to
Western blot analysis using anti-ATX and anti-RasGAP antibodies; the Y40/51/21 cells shown in the right panel were harvested on day 2. Parallel
experiments were performed on the conditioned medium, but we were unable to detect ATX. This may be due to factors such as the sensitivity
of the ATX antibody, sequestration of ATX by the collagen gel, and/or degradation of secreted ATX in the context of a tube assay. (B) Parental
BRECs were subjected to the standard VEGF-A-driven tube assay, and once the tubes had formed buffer, glycine (Gly) or L-histidine (His) was
added to a final concentration of 10 mM. (C) HUVECs were transfected with either siRNA for ATX or nontargeting control siRNA (CON) and
subjected to the VEGF-A-driven tube assay. The inset shows an anti-ATX Western blot of total cell lysates. The blot was reprobed with an anti-Erk
antibody to verify equivalent protein loading. ATX expression was decreased by an average of 70% in siRNA ATX-transfected cells. (D) BRECs
stably expressing the Y40/51 PDGFR mutant were subjected to a tube assay. Once tubes were formed, purified wild-type ATX (0.3 g/ml) or
inactive mutant ATX T210A (0.3 g/ml) was added. After 24 h, three randomly selected fields were photographed and tube lengths were measured.
The bar graphs show the means  standard deviations for three wells/treatment.
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FIG. 4. The ATX product LPA is responsible for tube regression. (A) BRECs stably expressing the Y40/51 PDGFR mutant were subjected to
a tube assay. After 24 h, fresh medium containing 10 M LPA or buffer was added. (B and C) Parental BRECs were subjected to the standard
VEGF-A-driven tube assay. Once the tubes had formed, buffer, LPA (10 M), and/or cyclosporine (1 M) was added. (D) HIMECs were
subjected to a tube assay. After 6 h, LPA (10 M) was added to the culture medium. Time-lapse images of tubes were captured, and serial images
are presented. (E) Same as panel A, expect that S1P (10 M) was added instead of LPA. (F) Same as panel E, expect that parental BRECs were
using instead of the BRECs expressing the Y40/51 PDGFR mutant. (G) BRECs stably expressing LPP1 were subjected to the standard
VEGF-A-driven tube assay. The inset is an anti-Flag Western blot of lysates prepared from empty vector (EV) or LPP1-expressing cells; the
RasGAP blot is induced as a loading control. (H) BRECs stably expressing the Y40/51 PDGFR mutant were subjected to a tube assay. This
experiment differed from the standard tube assay in that serum-free medium was used instead of medium containing 10% horse serum. Purified
WT ATX (0.3 g/ml) or inactive mutant ATX T210A (0.3 g/ml) was added once the tubes had formed (at the 18- to 24-h time point), and the
tube lengths were measured after 18 to 24 h of exposure to ATX. (I) Same as panel H, expect that ATX and LPC (10 M) were added instead
of catalytically inactive ATX. (J) BRECs were subjected to a migration assay using a Boyden chamber in the presence or absence of 1 M LPA.
The migrating cells were quantified as described in Materials and Methods. The means standard deviations from three independent experiments
are presented in the bar graph.
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even though regression was faster in the PLC/ mice. We
were unable to measure the amount of ATX protein in hyaloid
vessels (unpublished observations), and it remains an open
question whether the amount of ATX produced by these cells
is associated with the difference in the rate of regression be-
tween the two genotypes. Responsiveness to LPA is also de-
pendent on additional variables such as the presence of LPA
inhibitors, the expression and activity of LPPs, and the type
and level of LPA receptors expressed (39, 47). Further studies
are required to determine the underlying reason for delayed
regression of hyaloid vessels in the PLC/ mice.
The most common mechanism thought to account for vessel
regression is growth factor deprivation-induced apoptosis.
Pathological vessels in tumors and within numerous ocular
beds undergo at least partial regression in response to anti-
VEGF therapy (5). Regression can also be induced by the
microenvironment of the vasculature, and this information can
come in the form of soluble factors that are produced by other
cell types (13). Thus, there appear to be multiple ways to
induce regression of vessels; this information is likely to guide
efforts to enhance current antiangiogenic therapies.
Our findings indicate that endothelial cells within a tube can
generate factors that promote their destabilization, which in
certain settings can lead to regression. We call this pathway the
intrinsic destabilization pathway (IDP) (Fig. 6). The key events
in this pathway include activation of PLC, which leads to
increased production of ATX/LPA. LPA acts through its cell
surface receptors to activate RhoA/ROCK and induce a vari-
ety of cellular responses, including motility, which should de-
stabilize the cell-cell interactions needed to maintain organi-
zation within tubes/vessels and thereby facilitate regression.
Time-lapse studies indicate that as tubes regressed, they first
collapsed (Fig. 4D) and then underwent apoptosis (14).
Since proangiogenic factors such as VEGF and bFGF acti-
vated PLC (and hence the IDP), why are these agents best
known for their ability to facilitate the formation of new vessels
instead of inducing their regression? We speculate that activa-
tion of the IDP results in destabilization of a stable vascular
bed and hence is an essential, early step in the formation of
new vessels. Activation of the IDP in an unstable vascular bed
(newly formed or compromised due to diabetes-induced loss of
pericytes that occurs in the retina) would result in regression.
Thus, the state of the vascular bed may determine whether
engaging the IDP promotes angiogenesis versus regression.
How does the IDP relate to our earlier findings that PLC
induces regression by competing with PI3K for substrate? We
previously focused on PLC’s ability to reduce the output of
PI3K/Akt as a means to attenuate signaling events necessary
for tube formation and stability (14). An additional conse-
quence of the increased consumption of PtdIns-4,5-P2 by
PLC would be production of regression factors such as ATX/
LPA. The discovery of the IDP reveals that PLC not only
reduces the output of PI3K (and thereby limits tube formation)
but also initiates a series of events that leads to production of
secreted regression factors.
FIG. 5. Regression of hyaloid vessels is accelerated in ATXTg/ mice. (A) At postnatal days 1, 3, 7, 10, and 22, mice were euthanized, and the
eyes were removed, fixed, and sectioned. Sections were stained with hematoxylin and eosin, and representative sections prepared from P1 mice
are shown; the lower panels are high-magnification photos in which arrows point to the hyaloid vessels. The bar is 50 m. (B) The nuclei within
hyaloid vessels were counted as described in Materials and Methods, and the result for each eye is shown. There was a statistically significant
difference between the two groups at the first two time points.
FIG. 6. Schematic diagram of the intrinsic destabilization pathway
(IDP). Angiogenic growth factor receptors engage PLC, which acti-
vates calcineurin and leads to an increase in ATX. ATX is a secreted
form of phospholipase D, which converts lysophosphatidylcholine into
lysophosphatidic acid (LPA). We postulate that an increase in LPA
drives regression by first promoting migration of endothelial cells,
which destabilizes/disorganizes the vessel. The events shown in bold
are the focus of this report, while those in gray are from previous
publications (14, 15), and control tube formation or regression.
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Our findings that hyaloid vessel regression was aberrant in
mice that under- or overexpress members of the IDP lead to
the question of how this relates to Wnt- and Ang2-dependent
events, which regulate regression of this vascular bed (35). In
other settings, Wnts regulate the level of ATX (18, 34) and
induce ATX in tumors (19, 42, 49). Whether Wnts and/or
Ang2 control the level and/or activity of ATX in vascular
endothelial cells is an open question. Alternatively, Wnts and
Ang2 may influence the expression of LPA receptors or the
ability of these receptors to induce the signaling events that are
required for regression (such as Rho/ROCK activation [15,
28]). Furthermore, while our findings support a role for ATX/
LPA, they do not rule out the involvement of other regression
factors. Ongoing studies are focused on addressing these ques-
tions.
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